813 CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect

• Yan Zhang,
• Xu Wang,
• Peng Zhang,
• Pan Zheng,
• Xuexiang Du,
• Mingyue Liu,
• Juanjuan Su

Affiliations

Yan Zhang

Department of cardiology, Peking University First Hospital, Beijing, China

Xu Wang

Department of Biostatistics, University of Washington, Seattle, Washington, USA

Peng Zhang

Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Pan Zheng

Division of Immunotherapy, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA

Xuexiang Du

3University of Maryland Baltimore, Jinan, China

Mingyue Liu

3University of Maryland Baltimore, Jinan, China

Juanjuan Su

1IHV/UMB, Baltimore, MD, United States